Clinical antiviral effects of telbivudine in patients with chronic hepatitis B.
- VernacularTitle:替比夫定治疗慢性乙型肝炎108周的临床疗效
- Author:
Yan XU
1
;
Jiang-bin WANG
;
Shang-wei JI
;
Yong-gui ZHANG
;
Na-la SIQINGTU
;
Ping ZHAO
;
Hong-hua GUO
;
Yan LI
;
Jian JIAO
;
Chang-yu ZHOU
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Antiviral Agents; therapeutic use; DNA, Viral; blood; Female; Hepatitis B e Antigens; blood; Hepatitis B virus; genetics; physiology; Hepatitis B, Chronic; drug therapy; virology; Humans; Male; Middle Aged; Nucleosides; therapeutic use; Pyrimidinones; therapeutic use; Thymidine; analogs & derivatives; Treatment Outcome; Virus Replication
- From: Chinese Journal of Hepatology 2010;18(4):259-262
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo analyze antiviral effects of telbivudine in patients with chronic hepatitis B.
METHOD72 chronic hepatitis B patients without prior history of antiviral therapy were treated with telbivudine 600mg once daily.
RESULTSAt week 4, 37.5% of the patients achieved undetectable HBV DNA, and 33.3% achieved ALT normalization. At week 108, 87.5% of the patients achieved undetectable HBV DNA, and 91.7% achieved ALT normalization. HBeAg seroconversion occurred in 23.9% of the 46 HBeAg positive patients. The rates of undetectable HBV DNA and HBeAg seroconversion at week 108 in the patients with HBV DNA < 3 log(10) copies/ml at week 12 were significant higher than those in patients with HBV DNA >or= 3 log(10) copies/ml. The rate of undetectable HBV DNA at week 108 in the patients with HBV DNA < 3 log(10) copies/ml at week 24 was significantly higher than that in patients with HBV DNA >or= 3 log(10) copies/ml, and the rate of antiviral resistance rate at week 108 in the patients with HBV DNA < 3 log(10) copies/ml at week 24 was significantly lower than that in patients with HBV DNA >or= 3 log(10) copies/ml. Antiviral therapy could significantly improve Child-Pugh score in patients with liver cirrhosis.
CONCLUSIONTelbivudine treatment results in suppression of HBV and high HBeAg seroconversion, and improvement of Child-Pugh score in the patients with liver cirrhosis.
